The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psori
about
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?Nonmedical Switching of Biosimilars in Patients With Inflammatory Bowel Disease.Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.GP2015: An Etanercept Biosimilar.Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence.Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015.An update on the clinical evidence that supports biosimilar approvals in Europe.Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately respondinA New Venue of TNF Targeting.Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin AmericaFocus on biosimilar etanercept - bioequivalence and interchangeabilityThe biosimilars journey: current status and ongoing challengesReview of Biosimilar Trials and Data on Adalimumab in Rheumatoid ArthritisBiosimilar switching - current state of knowledgeNon-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
P2860
Q33840949-65F30A4A-A178-402F-9410-B8B748F4CB02Q38708927-F30ADD75-7262-45ED-8B2D-9F086EC58912Q38992643-D87C8F7A-8D8B-4F6E-83E5-1FAD5D03F16BQ42360803-D57BB7BC-8AC3-4EED-A2B2-F4115C64E3A4Q47110381-643C2CE9-A2D4-402B-B439-1812FBF0953EQ47688424-87238DEB-3D4B-42CD-9F2E-E97CE7CEC090Q47757431-A0F64BCD-CB6A-4586-B9B9-6A1EB341CA45Q47901584-7BDAEF67-EBD3-48C3-A1C0-5398CB36FEF3Q48216426-4E2E660B-AF16-4F6B-8ABF-886FA0B9B10DQ49693642-E0E408DD-80BC-4578-9B26-4FAED976CAF3Q49979586-457A99F7-16CC-44D6-AF3B-41C0C565F82FQ50098933-7FD59B78-E599-4703-9444-03B8205D7F5DQ52343061-7837906B-7D67-40E4-B69B-DFECE381447CQ52651099-A372BA8E-6675-440F-8976-DF53D050F0A6Q54967818-DD5E4272-78F5-4ACF-BE5C-618B796D8D24Q55001725-25F8A3B4-319B-4729-991C-9E84BDA87F8BQ55008089-CE78D36B-2D22-424B-9A55-B6864274A780Q57173064-41FD0E92-23BF-498A-9081-EFDCD27A1A9DQ57210818-2C16B5EF-C500-4B70-87D5-AC4EF896C8CDQ57298628-C4BDF8DC-F1C0-4848-98E3-1AC5BBC82334Q57741141-697972E4-2E7B-4928-A9AB-1273FBFECDCAQ58779818-FC9D42BE-3FE4-42EB-AB04-CF7769024743Q58798380-8E6B12FF-EA5F-44CC-B4B1-89318CFAED5B
P2860
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psori
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
The EGALITY study: a confirmat ...... vere chronic plaque-type psori
@en
The EGALITY study: a confirmat ...... vere chronic plaque-type psori
@nl
type
label
The EGALITY study: a confirmat ...... vere chronic plaque-type psori
@en
The EGALITY study: a confirmat ...... vere chronic plaque-type psori
@nl
prefLabel
The EGALITY study: a confirmat ...... vere chronic plaque-type psori
@en
The EGALITY study: a confirmat ...... vere chronic plaque-type psori
@nl
P2093
P2860
P356
P1476
The EGALITY study: a confirmat ...... vere chronic plaque-type psori
@en
P2093
EGALITY study group
H Woehling
J Weglowska
N Hattebuhr
P2860
P304
P356
10.1111/BJD.15152
P407
P577
2016-10-27T00:00:00Z